Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304)
Andrisha-Jade Inderjeeth, Andrew J. Martin, Robert R. Zielinski, Stephen Begbie et autres
BACKGROUND AND OBJECTIVE: ENZAMET randomised 1125 participants with metastatic hormone-sensitive prostate cancer to receive enzalutamide or a standard nonsteroidal antiandrogen (NSAA) combined with testosterone suppression with or without docetaxel. Enzalutamide demonstrated superior progression-free and overall survival (OS). Radiographic progression without prior/concurrent prostate-specific …
au, gb, nz, ie, ca (code pays fourni par la source)